表1：循环外泌体免疫肿瘤检查点和细胞因子是监测非小细胞肺癌患者抗PD-1/PD-L1治疗肿瘤反应的潜在生物标志物

数据集获取（Figshare）

• 源站标题：Table_1_Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.docx
• DOI：10.3389/fimmu.2022.1097117.s001
• 发布日期：2023-01-18
• 文件数：1 个
• 文件总体积：17.44 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Circulating_exosomal_immuno-oncological_checkpoints_and_cytokines_are_potential_biomarkers_to_monitor_tumor_response_to_anti-PD-1_PD-L1_therapy_in_non-small_cell_lung_cancer_patients_docx/21914781

命令行下载

curl -L -o "Table_1_Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therap.docx" "https://ndownloader.figshare.com/files/38874861"

文件清单

• Table_1_Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therap.docx（17.44 KB）

文件总体积 17.44 KB（源站 API 实测）。

数据说明

Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of biomarkers associated with responses are mandated in order to increase the efficacy of such therapy. In this study we evaluated 27 serum-derived exosomal immuno-oncological proteins and 44 cytokines/chemokines before and after ICIs therapy in 17 NSCLC patients to identify surrogate biomarkers for treatment/monitoring patient stratification for maximum therapeutic benefit. We first confirmed the identity of the isolated exosomes to have their specific markers (CD63, CD81, HSP70 and CD91). We have demonstrated that baseline concentration of exosomal-PD-L1 (p<0.0001), exosomal-PD-L2 (p=0.0413) and exosomal-PD-1 (p=0.0131) from NSCLC patients were significantly higher than their soluble-free forms. Furthermore, the exosomal-PD-L1 was present in all the patients (100%), while only 71% of patients expressed tissue PD-L1. This indicates that exosomal-PD-L1 is a more reliable diagnostic biomarker. Interestingly, exosomal-PD-L2 expression was significantly higher (p=0.0193) in tissue PD-L1-negative patients compared to tissue PD-L1-positive patients. We have also shown that immuno-oncological proteins isolated from pre-ICIs treated patients were significantly higher in exosomes compared to their soluble-free counterparts (CD152, p=0.0008; CD80, p=0.0182; IDO, p=0.0443; Arginase, p<0.0001; Nectin-2, p<0.0001; NT5E, p<0.0001; Siglec-7, p<0.0001; Siglec-9, p=0.0335; CD28, p=0.0092; GITR, p<0.0001; MICA, p<0.0001). Finally, the changes in the expression levels of exosomal immuno-oncological proteins/cytokines and their correlation with tumor response to ICIs treatment were assessed. There was a significant downregulation of exosomal PD-L1 (p=0.0156), E-Cadherin (p=0.0312), ULBP1 (p=0.0156), ULBP3 (p=0.0391), MICA (p=0.0391), MICB (p=0.0469), Siglec7 (p=0.0078) and significant upregulation of exosomal PD-1 (p=0.0156) and IFN- γ (p=0.0156) in responding patients. Non-responding patients showed a significant incr

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2022.1097117.s001（source: https://frontiersin.figshare.com/articles/dataset/Table_1_Circulating_exosomal_immuno-oncological_checkpoints_and_cytokines_are_potential_biomarkers_to_monitor_tumor_response_to_anti-PD-1_PD-L1_therapy_in_non-small_cell_lung_cancer_patients_docx/21914781）。